Literature DB >> 18510886

The changing epidemiology of pneumococcal pulmonary disease in the era of the heptavalent vaccine.

Catherine A Lexau1.   

Abstract

Since the pediatric pneumococcal 7-valent conjugate vaccine was licensed in the United States, dramatic changes have taken place in the occurrence of pneumococcal disease among children and adults. Incidence of invasive pneumococcal disease including bacteremic pneumonia has declined, but changes in noninvasive pulmonary disease have been more difficult to assess. This paper reviews evidence of the epidemiologic features of invasive pneumococcal disease and community-acquired pneumonia among children and adults since 2000. Despite some increases in non-vaccine-type disease, its use has resulted in major reductions in incidence of invasive pneumococcal disease in all age groups, particularly that of antibiotic-resistant disease and of pediatric pneumococcal pneumonia. Several studies show that changes in circulating pneumococcal strains may be producing differential changes in disease incidence and disease presentation in several populations, including HIV-infected individuals and Alaska Natives.

Entities:  

Year:  2008        PMID: 18510886     DOI: 10.1007/s11908-008-0038-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  48 in total

1.  Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States.

Authors:  David J Farrell; Keith P Klugman; Michael Pichichero
Journal:  Pediatr Infect Dis J       Date:  2007-02       Impact factor: 2.129

2.  Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect?

Authors:  Matthew R Moore; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

3.  Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-10-06

4.  Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.

Authors:  Katherine Hsu; Stephen Pelton; Sudharani Karumuri; Dawn Heisey-Grove; Jerome Klein
Journal:  Pediatr Infect Dis J       Date:  2005-01       Impact factor: 2.129

5.  An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations.

Authors:  Carrie L Byington; LaShonda Y Spencer; Timothy A Johnson; Andrew T Pavia; Daniel Allen; Edward O Mason; Sheldon Kaplan; Karen C Carroll; Judy A Daly; John C Christenson; Matthew H Samore
Journal:  Clin Infect Dis       Date:  2002-01-03       Impact factor: 9.079

6.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

Authors:  Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

7.  Population-based impact of pneumococcal conjugate vaccine in young children.

Authors:  Katherine A Poehling; Bonnie J Lafleur; Peter G Szilagyi; Kathryn M Edwards; Ed Mitchel; Richard Barth; Benjamin Schwartz; Marie R Griffin
Journal:  Pediatrics       Date:  2004-09       Impact factor: 7.124

8.  Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children.

Authors:  Michael E Pichichero; Janet R Casey
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

Review 9.  Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.

Authors:  R Austrian
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

10.  Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.

Authors:  Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin
Journal:  Lancet       Date:  2007-04-07       Impact factor: 79.321

View more
  1 in total

Review 1.  Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.

Authors:  Tina Q Tan
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.